THE EPIC OBSERVATIONAL STUDY

史诗般的观察研究

• 批准号: 7605102
• 负责人: Frank J. Accurso
• 金额: $ 2.21万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605102
• 关键词: Age; Antibiotic Therapy; Bacteria; Cessation of life; Characteristics; Chronic; Clinical; Computer Retrieval of Information on Scientific Projects Database; Cystic Fibrosis; Disease; Enrollment; Funding; Goals; Grant; Infection; Institution; Length; Link; Observational Study; Outcome; Participant; Pseudomonas aeruginosa; Pulmonary Cystic Fibrosis; Research; Research Personnel; Resources; Risk; Risk Factors; Source; Treatment Protocols; United States National Institutes of Health; cystic fibrosis patients; follow-up

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Pseudomonas aeruginosa (Pa) is the most important bacteria in CF lung disease. Chronic Pa infection is associated with worse disease and earlier death in CF patients. Risk factors for early age at Pa acquisition, the impact of initial Pa infection on clinical outcomes, and the effect of various early antibiotic treatment regimens remain incompletely understood. A large, multi- enter, observational study will be conducted with two broad goals. First, the study will link to and enhance the Early Anti-Pseudomonal Therapy In Cystic Fibrosis (EPIC) trial by collecting pre-enrollment characteristics and post-trial follow-up on EPIC trial participants, and by providing a comparator group that receives "usual therapy" for first Pa isolation. Second, the risk factors for and clinical impact of initial Pa infection will be examined, and the association of type and length of treatment at initial infection with outcomes. This is an important study as there are no large multi-center studies in patients with CF which have evaluated 1) risk factors for and clinical outcomes of first Pa infection, and 2) the clinical and bacterial outcomes of early anti-Pa therapy. Such information is needed to identify high-risk characteristics for early Pa acquisition and treatments most beneficial to young patients with CF.

这个子项目是众多研究子项目之一